ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma

Tirabrutinib (TIR), a Burton’s tyrosine kinase inhibitory drug, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refractory PCNSL using TIR. Three patients, 48, 78 and 88...

Descripción completa

Detalles Bibliográficos
Autores principales: Onodera, Sho, Akimoto, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648228/
http://dx.doi.org/10.1093/noajnl/vdab159.093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648228/
http://dx.doi.org/10.1093/noajnl/vdab159.093

Ejemplares similares